NIH funds research on pan-coronavirus vaccines
![NIH-cancer-deaths](/sites/default/files/styles/900x400/public/2018-05/NIH-cancer-deaths.jpg?itok=fA6hKsa2)
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today awarded grants to Brigham and Women’s Hospital and two universities to research and develop vaccine candidates that provide broad protective immunity to multiple coronavirus strains.
“These new awards are designed to look ahead and prepare for the next generation of coronaviruses with pandemic potential,” said NIAID Director Anthony Fauci, M.D.
The Pan-Coronavirus Vaccine Development Program expects to award additional grants to projects in 2022.
Related News Articles
Headline
The AHA's Next Generation Leaders Fellowship July 25 announced its 36 fellows for 2025, who will each work with mentors to address a specific challenge to…
Headline
AHA is now accepting applications through Aug. 31 for the 2024 Rural Hospital Leadership Team Award, which honors a team that has displayed outstanding…
Headline
The International Hospital Federation has extended the nomination deadline to May 3 for its 2024 awards honoring excellence in hospitals and health care…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
During its Annual Membership Meeting April 14 in Washington, D.C., the AHA honored 2024 Board Chair Joanne Conroy, M.D., president and CEO of Dartmouth Health…